AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01493505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
Study NCT01485991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
Study NCT01485991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TVR
Description: TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
Study NCT02064842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
Study NCT02064842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule once daily taken orally on Day 1 in Part 1
Study NCT02064842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: RTV 30 mg (ie, 0.38 mL oral solution of RTV \[80 mg/mL strength\]) taken orally on Day 1 in Part 1 and on Days 1 to 7 in Part 2
Study NCT00915876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: paricalcitol 1 mcg QD x 8 weeks
Study NCT00915876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Paricalcitol 1 mcg QD x 8 weeks
Study NCT00665860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three pills per day for two years
Study NCT00665860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy isoflavones
Description: Three pills that delivered 80 mg of aglycone isoflavones per day for two years
Study NCT00665860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy isoflavones
Description: Three pills that delivered 120 mg aglycone isoflavones per day for two years
Study NCT02658955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short stitch
Description: Surgeons will receive instructions to change the technique of abdominal wall closure
Study NCT03105479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Granules for oral suspension to be administered twice daily
Study NCT03105479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin capsule
Description: Capsule containing 125 mg of vancomycin to be administered orally 4 times a day
Study NCT03105479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin solution
Description: Vancomycin powder to be administered as oral solution at a dose of 40 mg/kg/day, 3 to 4 times a day
Study NCT02626130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryoablation
Study NCT02626130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02626130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02626130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT00565643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified sodium hyaluronic acid and carboxymethylcellulose
Description: Adhesion barrier applied at the time of initial cesarean delivery
Study NCT00565643 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Routine abdominal closure without placement of adhesion barrier
Study NCT02363413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IniVAH
Description: Initiation of the NIV during a 3 days hospitalization as usual.
Study NCT02363413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IniVAD
Description: Initiation of the NIV at home. The first day, the kinesiologist and the technician start-up the NIV at home with the patient. The investigator will validate the adjustment settings proposed by the kinesiologist. No procedure during the second day as described by the HAS. The third day, the kinesiologist and the technician come back to the patient home so as to adjust the settings if needed and if validated by the investigator.
Study NCT01510795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
Study NCT03600194 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PowerSleep Stim
Description: The PowerSleep Stim device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. Soft audio tones (below 65dB) will be administered via the speakers system during deep sleep as determined by the functionality of the device. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
Study NCT03600194 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Northwestern Stim
Description: The Northwestern Stim Device will function similarly to the PowerSleep device, but stimulation will be provided using a standard PC (computer) setup at the bedside using standard PSG electrodes. EEG will be monitored and slow wave sleep (SWS) identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves and to control acoustic stimulation in a phase-locked manner (targeting the up phase of the slow wave). Acoustic stimulation will be provided by headphones with an audible soft volume that do not result in arousals.
Study NCT03600194 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PowerSleep Sham
Description: The PowerSleep Sham device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. There are no audio tones played in the Sham condition. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
Study NCT03600194 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NorthWestern Sham
Description: The Northwestern Sham device is set up will function similarly to the PowerSleep prototype. EEG will be monitored and SWS identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves. Participant will wear headphones but no audio tones played in the Sham condition.
Study NCT03396315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis
Study NCT03396315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
Study NCT02637401 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dialectical Behaviour Therapy
Study NCT01494155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
Study NCT01080469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 1 mg Capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study NCT01080469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 1 mg Capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study NCT00494052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart (Web-Based Decision Aid)
Description: Participants in the intervention group will access Heart to Heart, a Web site designed to educate them about their overall CHD risk, specific risk factors, and strategies and preferences for risk reduction.
Study NCT00494052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Education Session
Description: A physician education session will be included in the program.
Study NCT00644410 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stromal cell
Description: Mesenchymal stromal cells 20 - 40 mill.
Study NCT00644410 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 12 injection with 0.2 ml saline
Study NCT00879346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: 160mg oral single dose (4 x 40mg tablets)
Study NCT00381732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.
Study NCT00381732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth once a day for 24 weeks. Placebo patient will receive 5 mg tadalafil tablet during the open label extension.
Study NCT05189301 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: first pass study
Description: Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)
Study NCT05189301 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise testing
Description: to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)
Study NCT01494155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital
Study NCT01494155 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton or Photon Radiation Therapy
Description: Daily, beginning Week 2 for 5 consecutive days
Study NCT00215540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant 175 mg/kg
Description: Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).
Study NCT00215540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant 90 mg/kg
Description: Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
Study NCT00215540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
Study NCT00714922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK
Description: Laser refractive surgery
Study NCT00714922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBK
Description: Laser refractive surgery
Study NCT03356730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This group will receive vitamin D supplementation.~Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:~• 5,000 IU / day - 10 drops per day for two months.
Study NCT03356730 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This control group will receive placebo.~Placebo (olive oil mint flavor), oral suspension in drops, will be prescribed as follows:~• 10 drops per day for two months.
Study NCT00246337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to match assigned treatment arm; one orally-administered dose
Study NCT00246337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 25 mg; one orally-administered dose
Study NCT00246337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 50 mg; one orally-administered dose
Study NCT00246337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 100 mg; one orally-administered dose
Study NCT00246337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 200 mg; one orally-administered dose
Study NCT00246337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 300 mg; one orally-administered dose
Study NCT00246337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 400 mg; one orally-administered dose
Study NCT00246337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974
Description: MK0974 600 mg; one orally-administered dose
Study NCT00246337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan
Description: Rizatriptan 10 mg; one orally-administered dose
Study NCT03270514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
Study NCT03270514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
Study NCT03831984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,09% Bromfenac
Description: topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
Study NCT03831984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0,1% sodium hyaluronate
Description: topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
Study NCT04411602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 plasma
Description: To determine feasibility of convalescent plasma for treating patients in the ICU with COVID-19.
Study NCT01253863 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exploration
Description: exploration of wound for determining damaged tissue
Study NCT04642963 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac Radiosurgery
Description: Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate.
Study NCT01226511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally
Study NCT01226511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: Administered orally
Study NCT01226511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01840384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-micronutrients
Study NCT01840384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin and Lactose
Study NCT03077984 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chinese medicine treatment
Description: The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
Study NCT03566459 — intervention group
Intervention type: OTHER
Intervention: CBOC offering Tele-MOUD to Veterans
Description: CBOC offering medications for opioid use disorder (MOUD) using telemedicine
Study NCT03566459 — intervention group
Intervention type: OTHER
Intervention: CBOC not offering Tele-MOUD to Veterans
Description: CBOC not offering medications for opioid use disorder (MOUD) using telemedicine
Study NCT02850822 — intervention group
Intervention type: DRUG
Intervention: Demethylation drug
Description: Demethylation drug,such as Decitabine
Study NCT02850822 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy regimen
Description: Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
Study NCT04021927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ring Phototherapy
Description: The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
Study NCT03047278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial Blood Samples
Description: Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.
Study NCT03047278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Blood Samples
Description: Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.
Study NCT03047278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial Urine Samples
Description: Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
Study NCT03047278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Urine Samples
Description: Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
Study NCT04259931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: microbiome analysis
Description: gut microbiome composition of C. difficile infected patients with relapsing (basal, at the end of first treatment, at the begin of the relapses and at four and twelve weeks after definitive treatment) and non-relapsing ( basal and four and twelve week after treatment) , will be analyzed.
Study NCT03047278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 300 mg
Description: All patients were treated with oral single dose of gabapentin 300 mg.
Study NCT03047278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Description: All patients were treated with oral single dose of gabapentin 300 mg.
Study NCT03047278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine Hydrochloride 10 mg
Description: Patients of control group were treated with cetirizine hydrochloride, 10 mg, twice as day, orally, for five days.
Study NCT01675050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Description: 4 weeks of cyproheptadine or placebo with crossover to the other
Study NCT01675050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugar pill
Description: 4 weeks of cyproheptadine or placebo with crossover to the other